BioDelivery Sciences International Company Profile (NASDAQ:BDSI)

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.04. The business earned $8.70 million during the quarter, compared to analysts' expectations of $8.45 million. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. BioDelivery Sciences International's revenue for the quarter was up 74.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) EPS. View BioDelivery Sciences International's Earnings History.

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for BioDelivery Sciences International.

6 equities research analysts have issued 12 month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.42 in the next year. View Analyst Ratings for BioDelivery Sciences International.

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

• 1. According to Zacks Investment Research, "BioDelivery’s has secured improved positioning in six new managed care contracts providing preferred access to its key drug Bunavail since July last year, which is expected to boost the drug’s sales and profitability in 2017. Moreover, its second marketed drug Belbuca’s sales hit all-time high since the product was launched a year ago. However, the company recently discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates may also face sever competition as it targets a highly genericized and crowded market. Its share significantly outperformed the Zacks classified Medical-Biomed/Genetics market so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (7/17/2017)
• 2. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
• 3. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)

Some companies that are related to BioDelivery Sciences International include Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), Female Health Company (The) (VERU), Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL), BioLife Solutions (BLFS), Concordia International Corp. (CXRX), SCYNEXIS (SCYX), Evoke Pharma (EVOK), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), Histogenics Corporation (HSGX), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI) and Cellectar Biosciences (CLRB).

BioDelivery Sciences International's management team includes the folowing people:

• Frank E. O'Donnell Jr., M.D., Executive Chairman of the Board
• Mark A. Sirgo, Vice Chairman of the Board
• Ernest R. De Paolantonio CPA, Chief Financial Officer, Treasurer, Secretary
• Niraj Vasisht Ph.D., Senior Vice President of Product Development and Chief Technical Officer
• Peter L. Ginsberg, Vice President - Business Development
• William B. Stone, Lead Independent Director
• Timothy C. Tyson, Director
• Charles J. Bramlage, Independent Director
• Thomas W. D'Alonzo, Independent Director
• Barry I. Feinberg M.D., Independent Director

BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.23%), Stonepine Capital Management LLC (6.27%), Vanguard Group Inc. (3.54%), Ameriprise Financial Inc. (3.43%), Blair William & Co. IL (2.66%) and Bank of Montreal Can (1.30%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Charles Bramlage, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr, Thomas D'alonzo and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

BioDelivery Sciences International's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Vanguard Group Inc., Broadfin Capital LLC, Virtu KCG Holdings LLC and GRT Capital Partners L.L.C.. Company insiders that have sold BioDelivery Sciences International stock in the last year include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De and Samuel P Sears, Jr. View Insider Buying and Selling for BioDelivery Sciences International.

BioDelivery Sciences International's stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Stonepine Capital Management LLC, EAM Investors LLC, Hikari Power Ltd, Sterling Investment Management Inc., GSA Capital Partners LLP, Valley National Advisers Inc. and Advisor Group Inc.. Company insiders that have bought BioDelivery Sciences International stock in the last two years include Barry I Feinberg, Charles Bramlage, Niraj Vasisht, Paolantonio Ernest Robert De and Thomas D'alonzo. View Insider Buying and Selling for BioDelivery Sciences International.

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.80.